Skip to main content
letter
. 2021 Nov 18;34:79–82. doi: 10.1016/j.euros.2021.10.001

Fig. 2.

Fig. 2

TCGA analysis for MIBC patients and a putative model of a suppressive axis mediated by Siglec-6 and Siglec-7. (A–D) Overall survival (n = 403; A,C) and disease-specific survival (n = 390; B,D) analyses by (A,B) Siglec-7 and (C,D) both Siglec-6 and Siglec-7 tumor mRNA expression obtained from TCGA data for patients with MIBC. (C,D) Patients were first segregated on the basis of Siglec-7 levels (below and above the median value) and the two groups were subsequently divided into two subgroups on the basis of Siglec-6 levels (below and above the respective median values in the subgroups). (E,F) Putative model of a suppressive axis mediated by Siglec-6 and Siglec-7 in bladder cancer. (E) Bladder tumor cells weakly express ligands for Siglec-6 (S6L), which is increased by BCG therapy, and high level of Siglec-7 ligands (S7L). Intratumoral CD8+ T cells express Siglec-6 at low levels, which is upregulated by BCG therapy. Siglec-7 and its ligands are highly expressed on intratumoral NK cells and in bladder tumor, respectively. Siglec-6/S6L and Siglec-7/S7L interactions restrict cytotoxic functions of effector CD8+ T and NK cells, respectively. (F) Immune checkpoint inhibitors targeting Siglec-6 and Siglec-7 may restore the function of intratumoral CD8+ T and NK cells. BCG = bacillus Calmette-Guérin; MIBC = muscle-invasive bladder cancer; NK = natural killer; Siglec = sialic acid–binding immunoglobulin-like lectin; SL = Siglec ligand. * p < 0.05.